In 1987, a young researcher decided to seize the opportunity to build on the promise of molecular biology that had helped to create a critical mass of companies in the biotech arena. At that time, research into central nervous system disorders was in its infancy and Cephalon founder, scientist and CEO, Frank Baldino, Jr. PhD envisioned creating a different kind of company that would be a hybrid of the best assets, and hopefully none of the worst features, of pharmaceutical, biotech, and specialty pharmaceutical companies.
Over its first 20 years, Cephalon has invested approximately $2 billion on research and development of its compounds. The foundation of its research facility is in West Chester, Pa., only a few miles from its corporate headquarters in Frazer. Nearly fifty percent of its workforce in the Commonwealth is dedicated to research and development with scientists and other research specialists employed in this capacity. And ...
